[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE253359T1 - Antithrombotische mittel - Google Patents

Antithrombotische mittel

Info

Publication number
ATE253359T1
ATE253359T1 AT98920057T AT98920057T ATE253359T1 AT E253359 T1 ATE253359 T1 AT E253359T1 AT 98920057 T AT98920057 T AT 98920057T AT 98920057 T AT98920057 T AT 98920057T AT E253359 T1 ATE253359 T1 AT E253359T1
Authority
AT
Austria
Prior art keywords
antithrbotic
agents
formula
novel compounds
compounds
Prior art date
Application number
AT98920057T
Other languages
English (en)
Inventor
Jolie A Bastian
Nickolay Y Chirgadze
Michael L Denney
Matthew J Fisher
Robert J Foglesong
Richard W Harper
Mary G Johnson
Valentine J Klimkowski
Ho-Shen Lin
Michael P Lynch
Jefferson R Mccowan
Shawn C Miller
Jeffrey T Mullaney
Michael E Richett
Daniel J Sall
Gerald F Smith
Kumiko Takeuchi
Jennifer M Tinsley
Michael R Wiley
Minsheng Zhang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE253359T1 publication Critical patent/ATE253359T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT98920057T 1997-05-01 1998-04-30 Antithrombotische mittel ATE253359T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4533597P 1997-05-01 1997-05-01
PCT/US1998/008755 WO1998048800A1 (en) 1997-05-01 1998-04-30 Antithrombotic agents

Publications (1)

Publication Number Publication Date
ATE253359T1 true ATE253359T1 (de) 2003-11-15

Family

ID=21937290

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98920057T ATE253359T1 (de) 1997-05-01 1998-04-30 Antithrombotische mittel

Country Status (9)

Country Link
US (1) US6541499B1 (de)
EP (1) EP1019047B1 (de)
JP (1) JP2001523256A (de)
AT (1) ATE253359T1 (de)
AU (1) AU7270798A (de)
CA (1) CA2287984A1 (de)
DE (1) DE69819539T2 (de)
ES (1) ES2210747T3 (de)
WO (1) WO1998048800A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9900043D0 (sv) * 1999-01-11 1999-01-11 Astra Ab New use
EP1313721B1 (de) * 2000-08-08 2006-03-08 Ortho-McNeil Pharmaceutical, Inc. Nicht-imidazol aryloxyalkylamine als h3 rezeptor liganden
JPWO2006070878A1 (ja) * 2004-12-28 2008-06-12 アステラス製薬株式会社 カルボン酸誘導体またはその塩
PE20070182A1 (es) 2005-07-29 2007-03-06 Wyeth Corp Derivados cianopirrol-fenil amida como moduladores del receptor de progesterona
BRPI0709612A2 (pt) 2006-03-15 2011-07-19 Wyeth Corp composto de fórmula i; método para o tratamento de um distúrbio no sistema nervoso central relacionado ou afetado pelo receptor histamina-3 em um paciente que necessita deste tratamento; método para a inibição do receptor h3; composição farmacêutica; e processo para a preparação de um composto de fórmula i
CN101432261A (zh) * 2006-05-19 2009-05-13 惠氏公司 作为组织胺-3拮抗剂的n-苯甲酰基-吡咯烷-3-基胺和n-苄基-吡咯烷-3-基胺
PE20081152A1 (es) * 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
MX2009012734A (es) * 2007-05-24 2010-03-30 Wyeth Llc Derivados de azaciclilbenzamida como antagonistas de histamina-3.
US7803825B2 (en) 2007-07-16 2010-09-28 Wyeth Llc Aminoalkylazole derivatives as histamine-3 antagonists
TW200918062A (en) * 2007-09-12 2009-05-01 Wyeth Corp Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists
AP2010005202A0 (en) * 2007-09-12 2010-04-30 Wyeth Llc Isoquinolinyl and isoindolinyl derivatives as histamines-3 antagonists
EP3619196B1 (de) 2017-05-04 2022-03-30 Bayer CropScience Aktiengesellschaft 2-{[2-(phenyloxymethyl)pyridin-5-yl]oxy}-ethanamin-derivate und verwandte verbindungen als schädlingsbekämpfungsmittel z.b. für den pflanzenschutz
WO2019018562A1 (en) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3928177A1 (de) * 1989-04-08 1991-02-28 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JPH05507469A (ja) * 1990-04-13 1993-10-28 スミスクライン・ビーチャム・コーポレイション 置換ベンズイミダゾール
ZA928276B (en) 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.
US5374638A (en) * 1993-03-19 1994-12-20 Merck & Co., Inc. Six membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives used to treat asthma
US5552426A (en) * 1994-04-29 1996-09-03 Eli Lilly And Company Methods for treating a physiological disorder associated with β-amyloid peptide
DE4426625A1 (de) 1994-07-27 1996-03-14 Schering Ag 2-Phenylindole, Verfahren zu deren Herstellung, diese enthaltende pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln
WO1997025033A1 (en) 1995-10-31 1997-07-17 Eli Lilly And Company Antithrombotic diamines
DE122009000061I1 (de) 1996-04-19 2009-12-31 Wyeth N D Ges D Staates Delawa Östrogene Verbindungen

Also Published As

Publication number Publication date
DE69819539D1 (de) 2003-12-11
EP1019047A4 (de) 2001-06-13
EP1019047B1 (de) 2003-11-05
AU7270798A (en) 1998-11-24
EP1019047A1 (de) 2000-07-19
CA2287984A1 (en) 1998-11-05
DE69819539T2 (de) 2004-09-30
US6541499B1 (en) 2003-04-01
JP2001523256A (ja) 2001-11-20
WO1998048800A1 (en) 1998-11-05
ES2210747T3 (es) 2004-07-01

Similar Documents

Publication Publication Date Title
BG66085B1 (bg) Фенилаланинови производни
ATE297203T1 (de) Antithrombotische mitteln
EE200100485A (et) Uudsed ühendid ja kompositsioonid proteaasi inhibiitoritena
ATE284690T1 (de) Antithrombotische diamine
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
YU40701A (sh) Piperidini kao modulatori ccr5
ATE306261T1 (de) Antithrombosemittel
BRPI0108395B8 (pt) derivados de pirrolopirimidinona, processos de preparação e uso
CO5590918A2 (es) Formulaciones
SE0100569D0 (sv) New compounds
LV12291A (lv) Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai
ATE253359T1 (de) Antithrombotische mittel
SE9901077D0 (sv) Novel use
SE0102055D0 (sv) New Compounds
SE9804212D0 (sv) Compounds
SE0102440D0 (sv) New compound
SE9801494D0 (sv) Novel use
DE69828522D1 (de) Antithrombotische mittel
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
NO983444L (no) Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5<alfa>-reduktaseinhibitorer
NO983511D0 (no) Difenylstilbener som pro-legemidler for COX-2-inhibitorer
ATE274515T1 (de) Pyrazolopyridinderivate
SE9904128D0 (sv) Novel compounds
ATE268768T1 (de) Antithrombosemittel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties